ACM
NUVB icon

Aster Capital Management’s Nuvation Bio NUVB Stock Holding History

Aster Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.07K Buy
+1,420
New +$6.94K ﹤0.01% 687
2026
Q1 		– Sell
-1,426
Closed -$12.8K – 1179
2025
Q4 		$12.8K Buy
+1,426
New +$8.83K 0.01% 708

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Aster Capital Management's NUVB Position: Q2 2026 in Review

Aster Capital Management opened a new position in Nuvation Bio (NUVB) in Q2 2026: 1,420 shares worth $8.07K. The stake represents ﹤0.01% of the portfolio and ranks #687 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in NUVB as recently as Q4 2025.

Aster Capital Management first reported a position in NUVB in Q4 2025 and has held it in 2 quarters since. The position peaked at $12.8K in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Aster Capital Management held 1,420 shares of Nuvation Bio worth $8.07K as of Q2 2026.
  • Nuvation Bio was a new Aster Capital Management position in Q2 2026.
  • Nuvation Bio made up ﹤0.01% of Aster Capital Management's portfolio in Q2 2026, its #687 holding.
  • Aster Capital Management first reported a position in Nuvation Bio in Q4 2025 and has held it in 2 quarters since.
  • Aster Capital Management's Nuvation Bio position peaked at $12.8K in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.